Dr. James Cummings Joins OyaGen

Dr. James Cummings Joins OyaGen Inc. Board of Directors

Dr. James Cummings

Dr. James Cummings

OYAGEN INC. NAMES DR. JAMES CUMMINGS TO OYAGEN INC. BOARD OF DIRECTORS; WILL PROVIDE EXPERTISE ON COMPANY’S LEAD ANTIVIRALS FOR COVID 2, HIV AND EBOLA
Rochester NY- Business Wire
OyaGen Inc, announced today that Dr. James Cummings M.D. has been elected to the OyaGen Inc, Board of Directors. Dr. Cummings is currently the President & Member of the Board of Directors for ICON Government and Public Health Solutions (GPHS), a division of ICON plc a global provider of outsourced drug and device development and commercialization services to pharmaceutical, biotechnology, medical device and government and public health organizations. Prior to joining ICON, Dr. Cummings served as a physician in the US Army, including a tour in Iraq, reaching the rank of Colonel. Before joining GPHS, Dr. Cummings was Vice President of Clinical
Development at Novavax.

Dr. Cummings commented “I look forward to providing mission-critical guidance
development of Oya1 as a therapeutic agent in treating COVID-19 and Ebola as well as
for OyaGen’s platform of drugs to treat HIV and prevent other infectious diseases. Over
the past 20 years I have led numerous efforts in successful medical product
development, bringing lifesaving infectious diseases solutions forward, for the benefit of
humankind” said Dr. Cummings. “As an infectious diseases’ physician, product
developer and Board Member of OyaGen, Inc. I am highly enthusiastic for the
opportunity to advise the Company in the development of these much needed medical
treatments to licensure.”

Dr. Harold Smith, CEO and Founder of OyaGen welcomed Dr. Cummings to the Board
and commented that “We are very pleased and excited that Dr. Cummings has joined
OyaGen’s Board of Directors. His expertise and relationships in global healthcare and
clinical development requirements and, in particular, with the FDA, NIAID and the Dept.
of Defense bring critical insight to OyaGen at a time when the Company is initiating
clinical development of its lead antiviral compounds. I look forward to working with Dr.
Cummings as we grow OyaGen’s business and advance our exciting product portfolio
of antiviral compounds targeting SARS-CoV-2, Ebola and HIV.”

OyaGen Inc is a privately held Biotechnology Company located in Rochester NY.
OyaGen platform technology is focused on the identification and development of novel
therapeutics for the treatment of viral diseases with several leads in development for
HIV, Coronavirus and Ebola.

For more information on OyaGen, Inc., please visit the Company’s website at www.oyageninc.com and follow us on Facebook at www.facebook.com/OyaGeninc, or call OyaGen, Inc. at (585) 697-4351.